Clinical trial
Bevacizumab in Treating Patients With Recurrent or Progressive Glioma
NCT00337207 · Northwestern University, Other · Completed
Key facts
| NCT number | NCT00337207 |
|---|---|
| Title | Bevacizumab in Treating Patients With Recurrent or Progressive Glioma |
| Official title | A Phase II Safety Study of Bevacizumab in Patients With Multiple Recurrent or Progressive Malignant Gliomas |
| Lead sponsor | Northwestern University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Biological |
| Interventions | bevacizumab |
| Enrollment | 55 |
| Start date | Mar 1, 2006 |
| Primary completion | Nov 1, 2008 |
| Completion | May 1, 2009 |
| First posted | Jun 15, 2006 |
| Last update posted | Feb 7, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: